A new treatment for systemic sclerosis
Part of Skin clinical trials.
This study tests a new medicine (called GB261) given as an infusion for people with systemicsclerosis (scleroderma) that affects the skin widely. The goal is to see if it can reduce skin thickening and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of systemic sclerosis (scleroderma).
- You have the diffuse type, meaning the skin thickening is widespread.
- Your skin thickening score (mRSS) is 15 or higher.
- You have had scleroderma for 7 years or less.
- You have not responded well enough to other treatments, or your disease is still active.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests a new investigational medicine called PRO-203 for people with systemic sclerosis (scleroderma). It aims to see if the medicine can help control active disease that hasn't responded to other treatments.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
This trial tests an experimental tablet called TollB-001 to see if it can help people with a type of systemic sclerosis that affects the skin and internal organs. It may reduce symptoms and slow the disease.
This trial tests a new treatment called OL-CD19-GDT for people with systemic sclerosis or Sjögren's syndrome that hasn't responded to standard therapies. It aims to see if the treatment is safe and might help control the disease.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.